retatrutide south africa My Retatrutide | GLP-1R/GIPR/GCGR ligand |

Thyroid disorders and diabetes mellitus (DM) are common chronic endocrine disorders that often coexist

BMI requirements for GLP-1 qualification vary by medication and indication, but many adults with obesity or overweight with comorbidities qualify

Results at 68 weeks: Weight loss: 28.7% average at the 12mg dose (-71.2 lbs), 26.4% at the 9mg dose (-64.2 lbs), compared to 2.1% with placebo

Fatigue can occur both as a direct side effect and indirectly through several mechanisms related to how these medications work

4 Triangulate Everything Validate findings across multiple independent sources

FDA GLP-1 Safety Announcement: Zepbound FDA Safety Label Change and Revised Drug LabelThe revised drug label contains a complete list of FDA-approved indications, side effects, warnings, and more